MOSCOW, Russia, April 22, 2015
In an intense, caffeine-fueled 48-hour
brainstorming session, 100 computer programmers met in Moscow last week
to compete in "GeneHack 2015", a hackathon in which competitors used
their computer programming skills to organize, analyze and visualize
reams of biological data. Their ultimate goal -- leverage their computer
skills to unlock the genetic code of deadly diseases like cancer and
Alzheimer's disease and extend the human lifespan.
The event, held at the Moscow Institute of Physics and Technology, was the first international bioinformatics hackathon. The event underscored the amount of computer programming talent available in Russia's IT industry and the booming growth of bioinformatics,
an industry in which computer technology is used to manage and analyze
complex biological information. The bioinformatics industry, valued at a
$4.2 billion last year is estimated to reach $13.3 billion in value by
the end of 2020.
The more than 100 young scientists who participated in "GeneHack 2015" were selected from a pool of more than 300 computer scientists. To demonstrate their skills, they competed in 12 challenges, including database development, compilation, gene expression analysis, and cross platform normalization using NVIDIA GPU.
Because
of the growing need for bioinformatics researchers worldwide, Insilico
Medicine, Inc. has R&D resources in the US, UK, Poland, Israel,
Russia and R&D collaborations in Canada, Israel, Switzerland and
China.
Until the early 1990s,
biology and related fields required very little computer experience.
Now, however, the vast amount of data generated from the human genome
has made high-powered computer analysis of vast amounts of biological
information necessary. Life scientists with an expertise in "Big Data"
computer science, and statistics, have the skills needed for a
successful career in bioinformatics.
About InSilico Medicine
InSilico Medicine, Inc. is a Baltimore-based company utilizing advances in genomics and big data analysis for in silico drug discovery and drug repurposing for aging and age-related diseases. The company utilizes the GeroScope(TM), OncoFinder(TM) , Pathway Cloud Intelligence(TM) and PharmAtlas(TM) packages for aging and cancer research, pursues internal drug discovery programs, and provides services to pharmaceutical companies.
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/InSilico/Medicine/prweb12669881.htm
No comments:
Post a Comment